• About Us
  • Our Products
  • Our Science
  • Clinical Expertise
  • Newsroom
  • Contact
  • About Us
  • Our Products
  • Our Science
  • Clinical Expertise
  • Newsroom
  • Contact

Genomic Urine Test Detects Bladder Cancer from DNA Up to 12 Years Before Clinical Signs and Symptoms Appear

by admin | Apr 27, 2023 | Uncategorized

Advances in Next-Generation DNA Sequencing and Machine Learning Enable Rapid Analysis of Genetic Mutations to Determine Cancer Risk CHICAGO – May 1, 2023 – A new genomic urine test can help doctors accurately predict bladder cancer as many as 12 years before clinical...

New Studies on Convergent Genomics’ Urine Test for Bladder Cancer to be Presented at 2023 American Urological Association (AUA) Annual Meeting

by admin | Apr 25, 2023 | Uncategorized

CHICAGO, April 25, 2023 /PRNewswire/ — Convergent Genomics announced UroAmp, the company’s genomic urine test that uses next-generation DNA sequencing and machine learning to detect and monitor for bladder cancer, will be the subject of two new studies...

Contact us
425 Eccles Ave, South San Francisco, CA 94080
info@convergentgenomics.com
415-839-0077





Privacy Policy

Financial Conflict of
Interest Policy

References